98%
921
2 minutes
20
Prior studies have reported pulmonary function tests (PFT) before and after related and unrelated allogeneic hematopoietic stem cell transplantation (HSCT). However, limited data exist on the evaluation of lung function after haploidentical stem cell transplantation (HAPLO) with post-transplant cyclophosphamide (PTCY). We retrospectively reported the evaluation of PFTs at screening before HAPLO in 80 patients at 100 days and 1 year of follow-up. The proportion of surviving patients with available PFTs at 100 days and 1 year were 86% and 68%, respectively. During the follow-up period, four patients met the criteria for bronchiolitis obliterans syndrome and two for interstitial lung disease. Overall survival was 73% (95% CI 62-82%) at 2 years. We observed a significant reduction in diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for the most recent hemoglobin concentration (DLCOc) at 100 days after HAPLO. However, an overall substantial stable pulmonary function was observed at 1 year.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/10428194.2021.1984460 | DOI Listing |
Lung
September 2025
The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Belfast, Belfast BT9 7BL, UK.
Introduction: Rhinovirus (RV) is the leading cause of exacerbations of lung disease. A sensory neuronal model, derived from human dental pulp stem cells and differentiated into peripheral neuronal equivalents (PNEs), was used to examine RV's effects on airway sensory nerves. We investigated whether RV can directly infect and alter PNEs or whether it exerts effects indirectly via the release of mediators from infected epithelial cells.
View Article and Find Full Text PDFPulm Ther
September 2025
Department of Pulmonary Function Test, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Introduction: Preserved ratio impaired spirometry (PRISm) is an important phenotype of pulmonary function in clinical and public health practice. It is possible for some patients to have chronic obstructive pulmonary disease (COPD) at an early stage. At present there is little research on the association of PRISm with type 2 (T2) inflammation biomarkers.
View Article and Find Full Text PDFImmunol Invest
September 2025
Respiratory and Critical Care Medicine, The 940th Hospital of Joint Logistics Support Force of chinese PLA, Lanzhou, China.
Background: Pulmonary neuroendocrine cells (PNECs) are specialized airway epithelial cells with dual sensory and secretory functions. They release bioactive mediators --including neuropeptides such as calcitonin gene-related peptide (CGRP) and gastrin-releasing peptide (GRP), and neurotransmitters such as 5-hydroxytryptamine (5-HT) and γ-aminobutyric acid (GABA) --that regulate airway smooth-muscle tone, mucus production, and immune responses. In chronic obstructive pulmonary disease (COPD), these PNEC-derived mediators contribute to airway inflammation, remodeling, and smooth-muscle dysfunction.
View Article and Find Full Text PDFInd Health
September 2025
Dokuz Eylul University, Faculty of Medicine, Department of Occupational Medicine, Turkey.
Jockeys endure considerable physical and psychological demands, rendering them vulnerable to occupational injuries such as fractures, concussions, and soft tissue damage. This descriptive case series presents the medical and occupational histories of three professional jockeys with long-term disabilities following work-related accidents. Each individual commenced their jockey career in early adolescence.
View Article and Find Full Text PDFAnal Chim Acta
November 2025
Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, 266071, China. Electronic address:
Background: Lung ischemia-reperfusion injury (LIRI) is a pathological condition characterized by aggravated oxidative-inflammatory tissue damage that occurs upon blood flow restoration after ischemia. LIRI can lead to severe complications, including primary graft dysfunction in lung transplants and multi-organ failure. However, current treatments remain limited.
View Article and Find Full Text PDF